Phreesia (NYSE:PHR) Stock, Quote.Headers.trade-ideas

Phreesia

Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.

Costco.Shutterstock

News

Price Target

Markets

Analyst Ratings

Trading Ideas

ANVS

ASTH

BROS

CAVA

COST

LNTH

MCHP

TASK

Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday

Earnings

Penny Stocks

Small Cap

APDN

BDSX

VIGL

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock&#39;s current market price does not adequately reflect its higher earnings, it suggests potential for growth.

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Health Care

General

ENOV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LUNG

The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment paved the way for digital services.

5 Medical Info Systems Stock to Buy for a Stable Portfolio

Phreesia Inc

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Pharmagen Inc

PHarol SGPS SA

JP Morgan analyst Anne Samuel maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and raises the price target from $27 to $28.

JP Morgan Maintains Overweight on Phreesia, Raises Price Target to $28

Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and raises the price target from $29 to $31.

Truist Securities Maintains Buy on Phreesia, Raises Price Target to $31

Baird analyst Joseph Vruwink maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Outperform and raises the price target from $31 to $34.

Baird Maintains Outperform on Phreesia, Raises Price Target to $34

JMP Securities analyst Joe Goodwin reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Market Outperform and maintains $30 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Phreesia, Maintains $30 Price Target

RBC Capital analyst Sean Dodge reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Sector Perform and maintains $23 price target.

RBC Capital Reiterates Sector Perform on Phreesia, Maintains $23 Price Target

Canaccord Genuity analyst Richard Close maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $34 price target.

Canaccord Genuity Maintains Buy on Phreesia, Maintains $34 Price Target

DA Davidson analyst Robert Simmons maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $32 price target.

DA Davidson Maintains Buy on Phreesia, Maintains $32 Price Target

Needham analyst Ryan MacDonald reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $29 price target.

Needham Reiterates Buy on Phreesia, Maintains $29 Price Target

Guidance

Phreesia Sees FY 2025 Revenue $416M - $426M Vs $420.41M Est.; Sees FY 2025 Adj. EBITDA $26M - $31M

Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.35) by 11.43 percent. The company reported quarterly sales of $102.10 million which beat the analyst consensus estimate of $101.70 million by 0.39 percent. This is a 18.96 percent increase over sales of $85.83 million the same period last year.

Earnings Beats

Phreesia Q2 2025 GAAP EPS $(0.31) Beats $(0.35) Estimate, Sales $102.10M Beat $101.70M Estimate

Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $28.25, a high estimate of $30.00, and a low estimate of $25.00. This current average has decreased by 6.61% from the previous average price target of $30.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1725037234_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Phreesia by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Phreesia compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Phreesia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Phreesia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Phreesia</h2>
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
<h3>Phreesia's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Phreesia's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.72% as of 30 April, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Phreesia's net margin is impressive, surpassing industry averages. With a net margin of -19.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Phreesia's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Phreesia's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.31%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Phreesia Through 4 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health shares fell 0.4% to close at $38.20 on Wednesday. <a href="https://www.benzinga.com/quote/ASTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted the price target for Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) from $850 to $975. Baird analyst Peter Benedict maintained an Outperform rating. Costco shares fell 0.3% to close at $884.31 on Wednesday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush increased CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) price target from $90 to $100. Wedbush analyst Nick Setyan maintained an Outperform rating. CAVA shares fell 5.5% to close at $85.30 on Wednesday. <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim boosted the price target for Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) from $30 to $36. Guggenheim analyst Gregory Francfort maintained a Neutral rating. Dutch Bros shares fell 4.3% to close at $39.46 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc cut Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) price target from $27 to $25. Keybanc analyst Scott Schoenhaus maintained an Overweight. Phreesia shares fell 7% to close at $18.82 on Wednesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) price target from $167 to $174. Piper Sandler analyst Korinne Wolfmeyer maintained an Overweight rating. Kimberly-Clark shares gained 1% to close at $140.79 on Wednesday. <a href="https://www.benzinga.com/quotBe/KM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners raised Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) price target from $106 to $127. Leerink Partners maintained an Outperform rating. Lantheus shares jumped 36.7% to close at $106.18 on Wednesday. <a href="https://www.benzinga.com/quote/LNTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Sprouts TaskUs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) price target from $14 to $16. Baird analyst David Koning maintained an Outperform rating. TaskUs shares gained 3.1% to close at $14.54 on Wednesday. <a href="https://www.benzinga.com/quote/TASK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Annovis Bio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) price target from $23 to $30. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Annovis Bio shares fell 17.1% to close at $12.08 on Wednesday. <a href="https://www.benzinga.com/quote/ANVS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39726449/top-4-real-estate-stocks-that-could-lead-to-your-biggest-gains-in-q3">Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3</a></li>
</ul>

Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and lowers the price target from $27 to $25.

Keybanc Maintains Overweight on Phreesia, Lowers Price Target to $25

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1719856823_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Phreesia compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Phreesia's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Phreesia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Phreesia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Phreesia</h2>
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
<h3>Understanding the Numbers: Phreesia's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Phreesia displayed positive results in 3 months. As of 30 April, 2024, the company achieved a solid revenue growth rate of approximately 20.72%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -19.48%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Phreesia's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -7.82%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Phreesia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.31%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Phreesia Through 6 Analysts

Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $29 price target.

Truist Securities Maintains Buy on Phreesia, Maintains $29 Price Target

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward &mdash; when a stock&#39;s current market price does not adequately reflect its higher earnings, it suggests potential for growth.
But there is more to this whole P/E story. Because not only low P/E but also stocks with a rising P/E can also fetch strong returns. In this regard, investors can bet on the likes of CLEAR Secure (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/you#NYSE">YOU</a>), Applied DNA Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apdn#NASDAQ">APDN</a>), Phreesia (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phr#NYSE">PHR</a>), Vigil Neuroscience (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vigl#NASDAQ">VIGL</a>) and Biodesix (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdsx#NASDAQ">BDSX</a>).
<h3>Rising P/E: A Useful Tool</h3>
The concept is&nbsp;that as earnings rise, so should the price of the stock. As forecasts for expected earnings come in higher, strong demand for the stock should continue to push up its prices. After all, astock&#39;s P/E gives an indication of how much investors are ready to shell out per dollar of earnings.
Suppose an investor wants to buy a stock with a P/E ratio of 30. This means that he is willing to shell out $30 for only $1 worth of earnings as he expects earnings of the company to rise at a faster pace in the future owing to strong fundamentals.
So, if the P/E of a stock is rising steadily, it means that investors are assured of its inherent strength and expect some strong positives out of it.
Also, studies have revealed that stocks have seen their P/E ratios jump over 100% from their breakout point in the cycle. So, if you can pick stocks early in their breakout cycle, you can end up seeing considerable gains.
<h3>The Winning Strategy</h3>
In order to shortlist stocks that are exhibiting an increasing P/E, we chose the following as our primary screening parameters.
EPS growth estimate for the current year is greater than or equal to last year&#39;s actual growth
Percentage change in last year EPS should be greater than or equal zero
(These two criteria point to flat earnings or a growth trend over the years.)
Percentage change in price over four weeks greater than the percentage change in price over 12 weeks
Percentage change in price over 12 weeks greater than percentage change in price over 24 weeks
(These two criteria show that the price of the stock is increasing consistently over the said timeframes.)
Percentage price change for four weeks relative to the S&amp;P 500 greater than the percentage price change for 12 weeks relative to the S&amp;P 500
Percentage price change for 12 weeks relative to the S&amp;P 500 greater than the percentage price change for 24 weeks relative to the S&amp;P 500
(Here, the case for consistent price gains gets even stronger as it displays percentage price changes relative to the S&amp;P 500.)
Percentage price change for 12 weeks is 20% higher than or equal to the percentage price change for 24 weeks, but it should not exceed 100%
(A 20% increase in the price of a stock from the breakout point gives cues of an impending uptrend. But a jump of over 100% indicates that there is limited scope for further upside and that the stock might be due for a reversal.)
In addition, we place a few other criteria that lead us to some likely outperformers.
Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) can get through.
Average 20-day Volume greater than or equal to 50,000: High trading volume implies that the stocks have adequate liquidity.
Just these few criteria narrowed down the universe from over 7,700 stocks to just 57.
Here are five out of the 57 stocks:
CLEAR Secure: The Zacks Rank #1 &nbsp;company platform connects you to the cards in your wallet.
The year-over-year earnings growth estimate of YOU for the upcoming quarter is 77.61%.
Applied DNA Sciences: The Zacks Rank #2 company provides proprietary DNA-embedded biotechnology security solutions using non-human DNA that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion.
The year-over-year earnings growth estimate of APDN for the upcoming quarter is 14.81%.
Phreesia: The Zacks Rank #2 company provides a patient intake management platform. The company&#39;s SaaS platform engages patients in their care and provides a modern, consistent experience while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.
The year-over-year earnings growth estimate of PHR for the upcoming quarter is 15.99%.
Vigil Neuroscience:This Zacks Rank #2 company is a microglia-focused therapeutics company.
The year-over-year earnings growth estimate of VIGL for the upcoming quarter is 6.84%.
Biodesix: This Zacks Rank #2 company is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care.
The year-over-year earnings growth estimate of BDSX for the upcoming quarter is 13.70%.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
<a href="https://www.zacks.com/stock/news/2294197/why-you-should-bet-on-5-top-ranked-stocks-with-rising-p-e?cid=CS-BENZ-FT-analyst_blog|rw-2294197">To read this article on Zacks.com click here.</a>

The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment paved the way for digital services.
The medical info systems industry comprises companies that develop and market healthcare information systems. These companies offer software and hardware solutions to healthcare providers with secure access to real-time clinical, administrative and financial data in a time-efficient manner. Focus on patient satisfaction, security of patient data and&nbsp; cost control has increased the need for big data, 3D printing, blockchain and artificial intelligence.
The medical sector is one of the major adopters of AI, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster and more accurate diagnosis. One common application of AI has been in diagnostic settings, where it quickly and precisely detects image abnormalities that might be challenging for the human eye to spot.
Several medical device makers are also developing surgical robots with AI integration for complex and specialized procedures. Further, electronic health records, electronic medical records, predictive analytics and real-time alerting have been gaining prominence.
AI systems have been successful in multiple medical imaging use cases, such as detecting mitosis in breast cancer histology images, classifying skin cancer with dermatologist-level accuracy, diagnosing diabetic retinopathy from retinal fundus photographs and predicting cardiovascular risk factors from retinal fundus photographs.
Even though the pandemic is over, the need for contactless services is growing enormously. Within the medical information systems space, the telehealth and remote patient monitoring segments continue to grow at a fast pace.
The Zacks-defined Medical Info Systems Industry is currently in the top 25% of the Zacks Industry Rank. Since it is ranked in the top half of Zacks Ranked Industries, we expect the consulting services industry to outperform the market over the next three to six months.
<h3>Our Top Picks</h3>
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks have seen positive earnings estimate revisions in the last 60 days. Each of our picks carries a Zacks Rank#1 (Strong Buy) or 2 (Buy).
The chart below shows the price performance of our five picks year to date.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/92/69334.jpg?v=194732729" /> 
Image Source: Zacks Investment Research
Hims &amp; Hers Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. HIMS offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
HIMS also provides prescription medication on a recurring basis and ongoing care from healthcare providers, over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
Zacks Rank #1 Hims &amp; Hers Health has an expected revenue and earnings growth rate of 41.9% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 5.6% over the last seven days.
Enovis Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enov#NYSE">ENOV</a>) operates as a medical technology company focused on developing clinically differentiated solutions worldwide. ENOV also manufactures and distributes medical devices that are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. ENOV operates through the Prevention and Recovery, and Reconstructive segments.
Zacks Rank #2 Enovis has an expected revenue and earnings growth rate of 24.4% and 9.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.8% over the last 30 days.
Pulmonx Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lung#NASDAQ">LUNG</a>) is a commercial-stage medical technology company that provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. LUNG offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema, and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
LUNG also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis offering information on emphysema destruction, fissure completeness, and lobar volume to identify target lobes for the treatment with Zephyr Valves.
Zacks Rank #2 Pulmonx has an expected revenue and earnings growth rate of 21.3% and 0.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 8.4% over the last 60 days.
Phreesia Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phr#NYSE">PHR</a>) provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. PHR&#39;s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.
Zacks Rank #2 Phreesia has an expected revenue and earnings growth rate of 17.9% and 53%, respectively, for the current year (ending January 2025). The Zacks Consensus Estimate for current-year earnings has improved 20.3% over the last 30 days.
Standard BioTools Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lab#NASDAQ">LAB</a>) provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. LAB operates through two segments: Proteomics and Genomics.
LAB offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system that performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes, and Hyperion XTi imaging system, a spatial biology instrument.
LAB also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs, and IFC Controllers, a controller which is designed to work with IFC formats.
Zacks Rank #2 Standard BioTools has an expected revenue and earnings growth rate of 89.5% and 43.9%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 23.3% over the last 60 days.
<a href="https://www.zacks.com/stock/news/2292098/5-medical-info-systems-stock-to-buy-for-a-stable-portfolio?cid=CS-BENZ-FT-analyst_blog|investment_ideas-2292098">To read this article on Zacks.com click here.</a>

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$20.00</td>
<td>$570.0K</td>
<td>3.2K</td>
<td>3.1K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/07/24</td>
<td>$850.00</td>
<td>$87.7K</td>
<td>386</td>
<td>1.2K</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$30.00</td>
<td>$101.6K</td>
<td>1.4K</td>
<td>660</td>
</tr>
<tr>
<td>GPCR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$50.00</td>
<td>$86.6K</td>
<td>0</td>
<td>571</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$42.9K</td>
<td>12.6K</td>
<td>436</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$116.6K</td>
<td>4.2K</td>
<td>418</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$230.00</td>
<td>$61.2K</td>
<td>134</td>
<td>301</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/14/24</td>
<td>$230.00</td>
<td>$26.4K</td>
<td>61</td>
<td>157</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$26.0K</td>
<td>666</td>
<td>121</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$330.00</td>
<td>$27.4K</td>
<td>12</td>
<td>78</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>), we notice a put option trade that happens to be neutral, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 3000 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $570.0K, with a price of $190.0 per contract. There were 3204 open contracts at this strike prior to today, and today 3134 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on June 7, 2024. This event was a transfer of 283 contract(s) at a $850.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $87.7K, with a price of $310.0 per contract. There were 386 open contracts at this strike prior to today, and today 1278 contract(s) were bought and sold. 
• Regarding CORT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 654 contract(s) at a $30.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $101.6K, with a price of $160.0 per contract. There were 1416 open contracts at this strike prior to today, and today 660 contract(s) were bought and sold. 
• Regarding GPCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>), we observe a put option trade with neutral sentiment. It expires in 564 day(s) on December 19, 2025. Parties traded 85 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $86.6K, with a price of $1020.0 per contract. There were 0 open contracts at this strike prior to today, and today 571 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bullish, expiring in 228 day(s) on January 17, 2025. This event was a transfer of 90 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $478.0 per contract. There were 12652 open contracts at this strike prior to today, and today 436 contract(s) were bought and sold. 
• Regarding NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we observe a call option trade with bullish sentiment. It expires in 228 day(s) on January 17, 2025. Parties traded 299 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $116.6K, with a price of $390.0 per contract. There were 4211 open contracts at this strike prior to today, and today 418 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 153 contract(s) at a $230.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $61.2K, with a price of $400.0 per contract. There were 134 open contracts at this strike prior to today, and today 301 contract(s) were bought and sold. 
• Regarding BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we observe a call option sweep with bullish sentiment. It expires in 11 day(s) on June 14, 2024. Parties traded 44 contract(s) at a $230.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $600.0 per contract. There were 61 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $520.0 per contract. There were 666 open contracts at this strike prior to today, and today 121 contract(s) were bought and sold. 
• For HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we notice a put option sweep that happens to be bullish, expiring in 382 day(s) on June 20, 2025. This event was a transfer of 9 contract(s) at a $330.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $3050.0 per contract. There were 12 open contracts at this strike prior to today, and today 78 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BIIB

CORT

GPCR

NVAX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and lowers the price target from $35 to $29.

Truist Securities Maintains Buy on Phreesia, Lowers Price Target to $29

Phreesia, Inc. 2025 Q2 - Results - Earnings Call Presentation

Phreesia, Inc. (PHR) Q2 2025 Earnings Call Transcript

In a report released today, Aaron Kimson from JMP Securities maintained a Buy rating on Phreesia (PHR – Research Report), with a price target of $3...

Phreesia (PHR) Receives a Buy from JMP Securities

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Phreesia (PHR – Research Report), with a price target of $29.0...

Barclays Remains a Buy on Phreesia (PHR)

In a report released yesterday, Sean Dodge from RBC Capital maintained a Hold rating on Phreesia (PHR – Research Report), with a price target of $2...

RBC Capital Remains a Hold on Phreesia (PHR)

Needham analyst Ryan MacDonald reiterated a Buy rating on Phreesia (PHR – Research Report) today and set a price target of $29.00. Ryan MacDonald's...

Phreesia's Positive Financial Outlook and Attractive Valuation: A Buy Recommendation

In a report released today, Will Jellison from D.A. Davidson maintained a Buy rating on Phreesia (PHR – Research Report). The company's shares clos...

Phreesia (PHR) Receives a Buy from D.A. Davidson

Phreesia: Remain Bullish Given The Healthy Growth Outlook

Phreesia ($PHR) is at the focal point towards the transition to improved healthcare outcomes via patient-driven digital solutions, having partnered...

Phreesia (PHR) Improves Healthcare Outcomes and Expects Growing Clientele

Barclays analyst Stephanie Davis assigned a Buy rating to Phreesia (PHR – Research Report) today and set a price target of $29.00. The company's sh...

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Phreesia

Phreesia (PHR) Forecast

Phreesia (NYSE:PHR) Stock, Quote.Headers.trade-ideas